NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...
These Stocks Are Moving the Most Today: ASML, Nvidia, United Airlines, J.B. Hunt, DJT, Novocure, Morgan Stanley, and More
Stock futures traded mildly to the upside Wednesday and tech shares looked set for a slight rebound following a sharp slump ...
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat ...
FierceBiotech7h
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
Business Wire22h
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
STAT8h
A controversial approval for Novocure’s device
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
The Pharma Letter10h
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...